Whether process development, new technologies, or studies and therapies for genetic diseases, autoimmune disorders, and cancer: 22 projects from 13 cities are being supported with €9.5 million through the SPARK-BIH project funding program at the Berlin Institute of Health at Charité (BIH), as part of the National Strategy for Gene- and Cell-Based Therapies (GCT). The aim is to translate groundbreaking GCT research into concrete, viable, scalable, and patient-centered therapies.